Overview over cloning procedures to produce plasmids and AAV vectors co-encoding shRNAs and Ago2 (or Yfp as control). (A) Following replacement of two BbsI sites that we had originally used for shRNA expression from a U6 promoter with two BsmBI sites (step 1), the resulting cassette was merged with CMV promoter-driven Ago2 or Yfp (step 2).
Step 3 consists of shRNA insertion as annealed oligonucleotides. Not shown is a derivative of plasmid pCA2n ("n" indicates the encoded neomycin resistance cassette) engineered to express blasticidin (hence named pCA2b) instead of neomycin. (B) Details of the shRNA cloning procedure in which two annealed oligonucleotides with 5' CACC or AAAA overhangs, respectively, are ligated to compatible BbsI or BsmBI ends (steps 1 and 3 as in A). (C) Translation of the Ago2/shRNA co-expression strategy into an AAV vector plasmid context (steps 1-2 show the cloning scheme for the Ago2 co-encoding vector, and steps 3-4 for the Yfp control). Steps 5-6 symbolize the final shRNA cloning as annealed oligonucleotides, using identical overhangs as in B. Fire, Firefly luciferase; polyA, polyadenylation signal; Ren, Renilla luciferase; SV40, SV40 early promoter; T6, terminator signal for U6 promoter; tk, thymidine kinase promoter. In the plasmid in the figure center, ITR, rep and cap are the AAV inverted terminal repeats, or replication and capsid genes, respectively. Plasmid p10825 was from Addgene (see Methods). Numbers in brackets after BbsI and BsmBI indicate the nucleotides (5'-3'/3'-5' strand) following the enzyme binding site where cleavage occurs.
Supplementary Figure 2.
Additional validation 293T cells that Ago2 co-expression from an shRNA plasmid enhances RNAi. Shown is a comparison of luciferase knockdown efficiencies (normalized to the empty shRNA plasmid containing only the U6 promoter, set to 100%) with three different shRNAs expressed from a single shRNA/Ago2 plasmid (left), or from a separate construct that was cotransfected with the Ago2 expression plasmid (right). The cognate Yfp constructs were used as controls. Congruent with the data in Figure 2B , Ago2 mediated comparable improvements in RNAi when it was co-expressed in cis or in trans. Bars are means ± SD (n=3). Figure 2F in Ago2-over-expressing HeLaP4 cells. Note that overall knockdowns were enhanced, and that competition between the two shRNAs was reduced, as compared to the parental cells in Figure 2F . Extra Ago2 expression from the different plasmids had marginal to no effects (especially at the higher doses of target-specific shRNAs), proving that Ago2 no longer rate-limits RNAi in the stable cells (see also D). Bars are means ± SEM (n=6). (D) Additional validation that Ago2 no longer restricts RNAi in stable Ago2 cell lines. Luciferase knockdown assays after co-transfection with psiCheck2 and either the single Ago2/shRNA construct or two separate shRNA and Ago2 plasmids showed the typical RNAi enhancement in normal Huh7.5 cells (left half). In contrast, the presence or absence of ectopic Ago2 made no difference in stable Huh7.5-Ago2 cells (right half). Bars are means ± SD (n=3).
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Supplementary Figure 4.
Analysis of dysregulation of cellular gene expression profiles upon siRNA delivery. Parental HeLaP4 cells (top) or the cognate Ago2-over-expressing cell line (bottom) were transfected with the siRNA against Myo10 (siMyo10) or an unrelated control siRNA (siCtrl). Changes in endogenous gene expression between the two siRNAs in each cell line were determined using a stringent fold change cutoff of 2 0.5 (1.414) and a P-value cutoff of 0.01. As indicated by the dots and numbers, the total number of dysregulated genes was reduced from 460 to 268 in the Ago2-overexpressing clone. Moreover, there was a tendency towards milder alterations in the Ago2 cells. 
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